doc1-й российско - французский форум «общественное здоровье и
download 
Report Transcription
1-й российско - французский форум «общественное здоровье и
1er Forum franco-russe de santé publique et d’innovation médicale 1-Й РОССИЙСКО - ФРАНЦУЗСКИЙ ФОРУМ «ОБЩЕСТВЕННОЕ ЗДОРОВЬЕ И ИННОВАЦИИ В ЗДРАВООХРАНЕНИИ» ПРОГРАММА 30 ИЮНЯ – 1-ГО ИЮЛЯ 2016 ПОМЕЩЕНИЕ: Эндокринологический Научный Центр Москва общественность : 450 слушателeй по приглашению пресса, телеканал Регистрация, Распределение по университетам и Интернет Новое здание Эндокринологического Научного Центрa открыто Президентом Путином 1-ого июня, 2016 ПРОГРАММА : 2 дня, Синхронный перевод: Французский язык – Русский язык 2 PROGRAMME 30 juin - 1er juillet 2016 lieu : CENTRE DE RECHERCHE EN ENDOCRINOLOGIE 11, Dimitry Ulianov Str. MOSCOU Public : Participants sur invitation - Presse/Chaînes TV enregistrement / diffusion universités et Web. programme : Quatre demi-journées avec la première demi-journée comprenant la séance inaugurale et le point sur les relations entre la Russie et la France dans le domaine de la santé. Quatre demi-journées scientifiques conçues chacune selon le schéma suivant: - 4 orateurs russes et 4 orateurs français - 15 minutes de présentation et 10 minutes de discussion Traduction simultanée : Français - Russe 3 ЧЕТВЕРГ 30 ИЮНЯ 2016 1 ДЕНЬ 08:30 - РЕГИСТРАЦИЯ УЧАСТНИКОВ 09:00 - ОТКРЫТИЕ 1-ГО РОССИЙСКО-ФРАНЦУЗСКОГО ФОРУМА «ОБЩЕСТВЕННОЕ ЗДОРОВЬЕ И ИННОВАЦИИ В ЗДРАВООХРАНЕНИИ» ПРИВЕТСТВЕННОЕ СЛОВО УЧАСТНИКАМ ФОРУМА: Владимир Фортов - Президент Российской Академии Наук Вероника СКОРЦОВА - Министр здравоохранения, РФ Жан-Мари ДРЮ - Президент Фондa медицинской академии - ФMA Акад. Иван ДЕДОВ - Вице-президент Российской Академии Наук E.П. Жан-Морис РИПЭР - Посол Франции в России Проф. Клод Жафель - Вице-президент Национальной Академии Медицины РОССИЙСКО-ФРАНЦУЗСКИЕ ОТНОШЕНИЯ В ОБЛАСТИ ЗДРАВООХРАНЕНИЯ Модераторы Сессии : Акад. И.И. ДЕДОВ - Вице-президент Российской Академии Наук Проф. Андрей-Лоран ПАРОДИ - Почетный Председатель Национальной Медицинской Aкадемии 1 – Актуальный статус совместных биомедицинских и медицинских проектов России и Франции Alexis Michel - советник по науке и технологиям, посольство Франции 2 - ИССЛЕДОВАНИЕ NATION - РЕЗУЛЬТАТ УСПЕШНОГО РУССКО-ФРАНЦУЗСКОГО СОТРУДНИЧЕСТВА В СФЕРЕ ЗДРАВООХРАНЕНИЯ И.И. ДЕДОВ - Акад. Проф. РАН. М.В. ШЕСТАКОВА - член-корp. РАН. 10:45 - 11:15 - ПЕРЕРЫВ НА КОФЕ 3 – Российско-Французское сотрудничество в области биомедицинских исследований: история успеха Проф. Егор ВАССЕЦКИЙ - Директор исследования, CNRS, Ядерная Организация и Патологии, Гюстав Рюси институт 4 – Развитие биомедицинской науки в России Чехонин В.И. - Академик РАН Подписание трехсторонней конвенции РАН, ANM, FAM 12:00 - 13:00 - ОБЕД 12:00 - 13:30 - комната н°1 4 Сателлитный Симпозиум VYGON : Неонаталогия ( медецина, изучающая младенцев и новорожденных ) : внутренний опыт JEUDI 30 JUIN 2016 1ÈRE DEMI-JOURNÉE 08H30 - ACCUEIL 09H00 - DÉBUT DU 1er FORUM FRANCO-RUSSE DE SANTE PUBLIQUE ET D’INNOVATION MÉDICALE SÉANCE INAUGURALE : Introduction / présentation : Vladimir FORTOV - Président de l’Académie des Sciences de Russie Veronika SKORTSOVA - Ministre de la Santé et de la Famille, Fédération de Russie Jean-Marie DRU - Président, Fondation de l’Académie de Médecine Pr. Ivan DEDOV - Académicien, Vice-Président de l’Académie des Sciences de Russie Pr. Claude JAFFIOL - Vice-Président de l’Académie nationale de médecine S.E. Jean-Maurice RIPERT - Ambassadeur de France en Russie LES RELATIONS FRANCO-RUSSES DANS LE DOMAINE DE LA SANTÉ Président de séance : Pr. Ivan DEDOV - Académicien, Vice-président de l’Académie des Sciences de Russie Pr. André - Laurent PARODI - Président Honoraire de l’Academie nationale de médecine 1 - L’état actuel de la coopération biomédicale et médicale entre la France et la Russie Alexis MICHEL - Conseiller pour les Sciences et les Technologies à l’Ambassade de France en Russie 2 - Étude épidémiologique «Nation» - Résultat d’une collaboration franco-russe à succès dans le champ de la santé Pr. Ivan DEDOV - Académicien, Vice-Président de l’Académie des Sciences de Russie Pr. M. SHESTAKOVA - Membre correspondant de l’Académie des Sciences de Russie 10H45 - 11H15 - PAUSE CAFÉ 3 - La collaboration franco-russe dans la recherche Biomédicale : un succès Pr. Egor VASSETZKY - Directeur de recherche, CNRS, Laboratoire organisation nucléaire et Patholo gies, Institut Gustave Roussy 4 - Développement de la science biomédicale en Russie Pr. Vladimir TCHEKHONIN - Membre de l’Académie des Sciences de Russie Signature d’un protocole de coopération tripartite entre l’Académie des Sciences de Russie, la Fondation de l’Académie de Médecine et l’Académie nationale de médecine. 12H00 - 13H00 - DÉJEUNER - BUFFET 12H00 - 13H30 - Salle n°1 Symposium VYGON: «Néonatalogie: une expérience locale » 5 13:00 - ВОЗОБНОВЛЕНИЕ ФОРУМА САХАРНЫЙ ДИАБЕТ КАК УГРОЗА ДЛЯ СИСТЕМЫ ЗДРАВООХРАНЕНИЯ МОДЕРАТОРЫ СЕССИИ : АКАД. ИВАН ДЕДОВ - ВИЦЕ-ПРЕЗИДЕНТ РОССИЙСКОЙ АКАДЕМИИ НАУК ПРОФ. КЛОД ЖАФЁЛЬ - ВИЦЕ-ПРЕЗИДЕНТ, НMA 1 –ПАНДЕМИЯ ДИАБЕТА: ПРИЧИНЫ ПРОФ. БЭРЬНАРЬ БОДЮСО - ГЛАВА ЭНДОКРИНОЛОГИЧЕСКОГО ОТДЕЛА– БОЛЬНИЦА БЭЖЭН, СЭН МАНДЭ 2 – ПОДХОДЫ К ПРОФИЛАКТИКЕ САХАРНОГО ДИАБЕТА ПРОФ. ЖАН-ФРАНСОА ГОТЬЕ - ГЛАВА ДИАБЕТА ЭНДОКРИНОЛОГИЧЕСКОГО ОТДЕЛA, БОЛЬНИЦА ЛАРИБОАЗЕРЬ, ПАРИЖ 3 –ПРОГНОЗИРОВАНИЕ САХАРНОГО ДИАБЕТА 1 ТИПА В СЕМЬЯХ ВЫСОКОГО РИСКА В.А. ПЕТЕРКОВА - CПЕЦ. КОРP. РАН. Е.В. ТИТОВИЧ – К.М.Н. 15:30 - 16:00 - КОФЕ-БРЕЙК 4 - ДИАБЕТ И БЕРЕМЕННОСТЬ: НОВЫЕ ВОЗМОЖНОСТИ ПРОФ. АННА ВАМБЭРЬГ - ЭНДОКРИНОЛОГИЧЕСКОЕ ОТДЕЛЕНИЕ, CHRU HOSPITAL, LILLE 5 - ГЕНОМНОЕ, ПРОТЕОМНОЕ ПРОГНОЗИРОВАНИЕ ДИАБЕТИЧЕСКОЙ НЕФРОПАТИИ М.Ш.ШАМХАЛОВА – Д.М.Н. О.К.ВИКУЛОВА – К.М.Н. 6 - ЖИЗНЕННЫЙ ПУТЬ БОЛЬНОГО ДИАБЕТОМ ПРОФ. ЛИЗ БОРДЕ - ЭНДОКРИНОЛОГИЧЕСКИЙ ОТДЕЛ, ГОСТИНИЦА БЭЖЭН, СЭН МАНДЭ 7 - КЛЭМП-ТЕХНОЛОГИИ В ЭНДОКРИНОЛОГИИ А. Ю. МАИОРОВ – Д.М.Н., ПРЕЗИДЕНТ РОССИЙСКОЙ ДИАБЕТИЧЕСКОЙ АССОЦИАЦИИ 8 – ПЕРСОНАЛИЗИРОВАННАЯ ЭНДОКРИНОЛОГИЯ А.Н.ТЮЛЬПАКОВ – Д.М.Н., ЗАВ. ЛАБОРАТОРИЕЙ ГЕНЕТИЧЕСКИХ ИССЛЕДОВАНИЙ ФГБУ ЭНЦ МИНЗДРАВА РОССИИ 17:00 - ЗАВЕРШЕНИЕ ПЕРВОГО ДНЯ ФОРУМА 6 2ÈME DEMI-JOURNÉE 13H00 - REPRISE DU FORUM LE DIABÈTE, UN PROBLÈME DE SANTÉ PUBLIQUE Président de séance : Pr. Ivan DEDOV - Vice-Président de l’Académie des sciences de Russie Pr. Claude JAFFIOL - Vice-Président de l’Académie nationale de médecine 1 - Pourquoi cette épidémie de diabète du diabète: une pandémie mondiale Pr. Bernard BAUDUCEAU - Société Francophone du Diabète 2 - Le diabète peut-il être évité? Pr. Jean-François GAUTIER - Chef du service de Diabéto-endocrinologie de l’hôpital Saint-Louis, Paris 3 - Diabète de type 1 : prédiction pour les familles à haut risque Pr. V.A. PETERKOVA - Membre correspondant de l’Académie des Sciences de Russie Dr. E.V. TITOVITCH - PhD 15H30 - 16H00 - PAUSE CAFÉ 4 - Diabète et grossesse : nouvelles perspectives Pr. Anne VANBERGUE - Service d’Endocrinologie, Centre Hospitalo-Universitaire, Lille 5 - Prédiction génomique et protéomique de la néphropathie diabétique Dr. Med. Sci. M. Sh. SHAMKHALOVA Dr. O.K. VIKOULOVA - PhD 6 - Le parcours de santé du patient diabétique Pr. Lyse BORDIER - Service d’Endocrinologie, Hôpital Bégin , Saint Mandé 7 - La technologie automatisée Patch-clamp en endocrinologie Dr. Med. Sci. A. Yu. MAYOROV - Président de l’Assocation russe du diabète 8 - L’endocrinologie personnalisée Dr. Med. Sci. A. N. TYULPAKOV - Chef du laboratoire des maladies génétiques 17H00 - FIN DE LA JOURNÉE 7 ПЯТНИЦA 1 ГО ИЮЛЯ 2016 2 ДЕНЬ 08:30 – РЕГИСТРАЦИЯ УЧАСТНИКОВ 09:00 – ПРОДОЛЖЕНИЕ РАБОТЫ ФОРУМА НОВЫЕ ВОЗМОЖНОСТИ ТЕРАПИИ ОНКОЛОГИЧЕСКИХ ЗАБОЛЕВАНИЙ МОДЕРАТОРЫ СЕССИИ : АКАДЕМИК РАН А. Г. РУМЯНЦЕВ - РОССИЙСКАЯ АКАДЕМИЯ НАУК ПРОФ. БЭРНАРЬ ЛОНОА - ПРЕЗИДЕНТ, МЕЖДУНАРОДНОГО КОМИТЕТA, НMA 1 - 70 ЛЕТ ОНКОЛОГИЧЕСКОЙ СЛУЖБЕ РОССИЙСКОЙ ФЕДЕРАЦИИ: ИТОГИ И ПЕРСПЕКТИВЫ ЧЛЕН-КОРР. РАН А. Д. КАПРИН - ФГБУ «НМИРЦ» МИНЗДРАВА РОССИИ 2 - ИНТЕГРИРОВАННЫЙ ПОДХОД К БОРЬБЕ СО ЗЛОКАЧЕСТВЕННЫМИ ЗАБОЛЕВАНИЯМИ ПРОФ. ЖАН-ПЬЕРЬ АРМАН - ИНСТИТУТ ГЮСТАВ РУСИ 3 – ПЕРСПЕКТИВЫ РОССИЙСКО-ФРАНЦУЗСКОГО СОТРУДНИЧЕСТВА В ОБЛАСТИ ОНКОЛОГИИ М.Р.ЛИЧИНИЦЕР – ФГБУ «РОНЦ ИМ. Н.Н.БЛОХИНА» МИНЗДРАВА РОССИИ. 4 - НОВЫЕ ТЕРАПЕВТИЧЕСКИЕ ВОЗМОЖНОСТИ В ВЕДЕНИИ ПАЦИЕНТОВ ПРОФ. АКСЭЛЬ ЛЭСЭН - ИНСТИТУТ ГЮСТАВ РУСИ, ЧЛЕН-КОРР. NMA 5 – ОПТИМИЗАЦИЯ АНАЛИЗА МОЛЕКУЛЯРНО-ГЕНЕТИЧЕСКИХ ПРОФИЛЕЙ ТКАНИ РМЖ ДЛЯ РЕШЕНИЯ ЗАДАЧ ПРОГНОЗА И МОЛЕКУЛЯРНОГО ФЕНОТИПИРОВАНИЯ А.Г.ТОНЕВИЦКИЙ, А.В.БОЖЕНКО, М.Ю.ШКУРНИКОВ – ФГБУ «НМИРЦ» МИНЗДРАВА РОССИИ, ФГБУ «РНЦРР» МИНЗДРАВА РОССИИ 6 – ТАРГЕТНАЯ ТЕРАПИЯ: ОТ ВОПРОСА ПРИВЕРЖЕННОСТИ К ВОПРОСУ ТЕРАПЕВТИЧЕСКОГО ПРОСВЕЩЕНИЯ ПРОФ. ЖАК РУЭС – ЧЛЕН ÓБЩЕСТВА МЕДИЦИНСКОЙ АКАДЕМИИ, НMA 7 – ПЕРСОНАЛИЗИРОВАННАЯ МЕДИЦИНА В ОНКОЛОГИИ: УСПЕХИ И ТРУДНОСТИ ПРОФ. ЖАН-ИВ БЛЭ - ЦЕНТР LEON BERARD, LYON, ЧЛЕН-КОРР. ANM 8 – РЕЗУЛЬТАТЫ ПРОСПЕКТИВНЫХ КООПЕРИРОВАННЫХ ИССЛЕДОВАНИЙ ЭФФЕКТИВНОСТИ ЛЕЧЕНИЯ РАКА У ДЕТЕЙ РОССИИ И СТРАН СНГ АКАДЕМИК РАН А. Г. РУМЯНЦЕВ, ПРОФЕССОР А. Г. КАРАЧУНСКИЙ - ФНКЦ ДГОИ ИМ. ДМИТРИЯ РОГАЧЕВА 8 9 - ЛОКАЛЬНАЯ ГИПЕРТЕРМИЯ В КОМБИНИРОВАННОМ И ЛУЧЕВОМ ЛЕЧЕНИИ БОЛЬНЫХ РАКОМ ГОРТАНИ И ГОРТАНОГЛОТКИ АКАДЕМИК РАН Е. Л. ЧОЙНЗОНОВ - ФГБНУ «ТОМСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ОНКОЛОГИИ» СО РАН 10 - ИДЕНТИФИКАЦИЯ НОВЫХ РЕГУЛЯТОРОВ ОБРАЗОВАНИЯ МЕТАСТАЗОВ. А. Ю. АЛЕКСАНДРОВА И СОАВТ., Д.Б.Н. - ФГБУ «РОНЦ ИМ. Н. Н. БЛОХИНА» МИНЗДРАВА РОССИИ 12:00 - 13:00 - ОБЕД 12:30 - 13:30 - КОМНАТА Н°1 САТЕЛЛИТНЫЙ СИМПОЗИУМ AIRBUS HELICOPTERS FOUNDATION: “МЕДИЦИНА КАТАСТРОФ” 9 VENDREDI 1ER JUILLET 2016 3ÈME DEMI-JOURNÉE 08H30 - ACCUEIL 09H00 - DÉBUT DU FORUM NOUVELLES MÉTHODES DE SOINS POUR LES PATIENTS ATTEINTS DE CANCER Président de séance: Pr. A.G. ROUMYANTSEV- Membre de l’Académie des Sciences de Russie Pr. Bernard LAUNOIS - Président du Comité International, Académie nationale de médecine 1 - 70ème anniversaire du département russe de cancérologie : résultats et perspectives Pr. A.D. KAPRIN - Membre correspondant de l’Académie des Sciences de Russie 2 - Une approche intégrée pour lutter contre le cancer Pr. Jean-Pierre ARMAND - Institut Gustave Roussy 3 - Collaboration russo-française en cancérologie : perspectives Pr. M.R. LITCHINITSER - Centre scientifique russe N. N. Blokhin de cancérologie 4 - La médecine personnalisée dans les sarcomes Pr. Axel LE CESNE - Institut Gustave Roussy, Membre correspondant de l’Académie nationale de médecine 10H15 - 10H45 - PAUSE CAFÉ 5 - L’optimisation de l’analyse du profil génétique moléculaire des tumeurs dans le cancer du sein favorise la meilleure prédiction du pronostic et le phénotypage moléculaire A. G. TONEVITSKY, A. V. BOJENKO, M. YU. SHKOURNIKOV - Centre national médical de recherche en radiologie - Ministère de la sante publique, Centre de recherche russe en radiologie - Ministère de la santé publique 6 - Les traitements ciblés : nouveaux progrès de la conformité à l’éducation thérapeutique: Cancer du sein: l’expérience du patient Pr. Jacques ROUESSE - Membre du bureau de l’ANM 10 7 - La médecine de précision dans le traitement du cancer: progrès et limites. La mutation n’est pas toujours le «driver» Pr. Jean-Yves BLAY - Directeur Général du centre Léon Bérard, Lyon, Membre correspondant de l’Académie nationale de médecine 8 - Résultats des études prospectives et coopératives dans le traitement du cancer pédiatrique en Russie et dans le CIS Pr. A. G. RUMYANTSEV - Membre de l’Académie des Sciences de Russie Pr. A. G. KARATCHONSKY - Centre fédéral Dmitri Rogachev de recherche en hematologie, oncologie et immunologie 9 - L’hyperthermie locale dans la thérapie complexe et la radiothérapie dans le cancer du larynx et laryngo-pharyngé Pr. E.L TCHOÏNZONOV - Institut de Tomsk de recherche en oncologie, Membre de l’Académie des Sciences de Russie 10 - Les nouveaux régulateurs dans l’identification des métastases Pr. A.YU ALEXANDROVA et coll. - Centre fédéral de Russie N.N. Blokhin en recherche en oncologie - Ministère de la sante publique 12H00 - 13H00 - DÉJEUNER - BUFFET 12H00 - 13H30 - Salle n°1 Symposium FONDATION AIRBUS HELICOPTER : «Médecine d’Urgence et de Catastrophe» 11 4-ЫЙ ПОЛДЕНЬ 13:00 - ВОЗОБНОВЛЕНИЕ ФОРУМА ИННОВАЦИЯ - ОБРАЗОВАНИЕ И ИССЛЕДОВАНИЕ МОДЕРАТОРЫ СЕССИИ : ВЛАДИМИР СТАРОДУБОВ – ВИЦЕ-ПРЕЗИДЕНТ РОССИЙСКОЙ АКАДЕМИИ НАУК (РАН) – РОССИЙСКАЯ АКАДЕМИЯ НАУК ПРОФ. ИВ ЖЮИЕ - АКАДЕМИК, ГЕНЕРАЛЬНЫЙ CЕКРЕТАРЬ ФОНДА МЕДИЦИЙНСКОЙ AКАДЕМИИ OR ДАНИЭЛЬ КУТЮРЬЕ – ПОСТОЯННЫЙ СЕКРЕТАРЬ 1 - ЭНДОКРИННЫЕ РАЗРУШИТЕЛИ: РОЛЬ В РОСТЕ ЗАБОЛЕВАЕМОСТИ СД2 ТИПА, ОНКОЛОГИЧЕСКИХ И ДРУГИХ ЗАБОЛЕВАНИЙ. ГИГИЕНИЧЕСКИЕ МЕРОПРИЯТИЯ И ИХ СТОИМОСТЬ ПРОФ. ФИЛИП БУЩАРЬ – РУКОВОДИТЕЛЬ ОТДЕЛЕНИЯ ЭНДОКРИНОЛОГИИ И РЕПРОДУКТВНОЙ МЕДИЦИНЫ 2 – ОТКРЫТЫЕ ОБРАЗОВАТЕЛЬНЫЕ ОНЛАЙН-КУРСЫ (MOOCS) ПРОФ. АЛЬБЕР-КЛОД БЭНАМУ - СТАРШИЙ СОВЕТНИК ФРАНКОГОВОРЯЩЕГО А КАДЕМИЧЕСКОГО АГЕНТСТВA 3 – СИСТЕМА ПОДГОТОВКИ МЕДИЦИНСКИХ КАДРОВ В РОССИЙСКОЙ ФЕДЕРАЦИИ. НОВЫЕ МЕТОДИКИ ДИСТАНЦИОННОГО ОБУЧЕНИЯ П.В.ГЛЫБОЧКО – АКАДЕМИК РАН, РЕКТОР ПМГМУ ИМ. И.М.СЕЧЕНОВА 4 – СТАТЕГИИ ВАКЦИНАЦИИ – ВЛИЯНИЕ НА ОБЩЕСТВЕННОЕ ЗДОРОВЬЕ ПРОФ. ФРАНСУА БРИКЕР – РУКОВОДИТЕЛЬ ОТДЕЛЕНИЯ ИНФЕКЦИОННЫХ ЗАБОЛЕВАНИЙ И ТРОПИЧЕСКОЙ МЕДИЦИНЫ, ГОСПИТАЛЬ LA PITIÉ SALPÊTRIÈRE HOSPITA, ПАРИЖ, ЧЛЕН ANM 5 – РАЗВИТИЕ НАЦИОНАЛЬНОГО КАЛЕНДАРЯ ПРИВИВОК В РАМКАХ СОВРЕМЕННОЙ ПАРАДИГМЫ ПРОФИЛАКТИЧЕСКОЙ МЕДИЦИНЫ Н.И.БРИКО – АКАДЕМИК РАН, ДИРЕКТОР ИНСТИТУТА ЭПИДЕМИОЛОГИИ МИНЗДРАВА РОССИИ 6 – ДЕТСКИЕ ИНФЕКЦИИ В РОССИИ: СОСТОЯНИЕ ПРОБЛЕМЫ И ПУТИ РЕШЕНИЯ Ю.В. ЛОБЗИН – АКАДЕМИК РАН, ДИРЕКТОР НИИ ДЕТСКИХ ИНФЕКЦИЙ 7 - ЗДРАВООХРАНЕНИЕ РОССИИ В СОВРЕМЕННЫХ УСЛОВИЯХ: ПУТИ СТАБИЛИЗАЦИИ И ВОЗМОЖНОСТИ РАЗВИТИЯ В.И.СТАРОДУБОВ - АКАДЕМИК РАН, ВИЦЕ-ПРЕЗИДЕНТ РОССИЙСКОЙ АКАДЕМИИ НАУК (РАН) ЗАВЕРШЕНИЕ РОССИЙСКО-ФРАНЦУЗСКОГО ФОРУМА «ОБЩЕСТВЕННОЕ ЗДОРОВЬЕ И ИННОВАЦИИ В ЗДРАВООХРАНЕНИИ» АКАД. И. И. ДЕДОВ - ВИЦЕ-ПРЕЗИДЕНТ РОССИЙСКОЙ АКАДЕМИИ НАУК ПРОФ. БЭРНАРЬ ШАРПЭНТЬЕ - ВИЦЕ-ПРЕЗИДЕНТ OMA 16:00 - ЗАВЕРШЕНИЕ РАБОТЫ ФОРУМА 12 4ÈME DEMI-JOURNÉE 13H00 - REPRISE DU FORUM INNOVATION, ENSEIGNEMENT ET RECHERCHE EN MÉDECINE Président de séance : Pr. Vladimir STARODOUBOV - Vice-Président de l’Académie des Sciences de Russie Pr. Yves JUILLET - Secrétaire Général de la Fondation de l’Académie de Médecine, Membre de l’Académie nationale de médecine 1 - Les perturbateurs endocriniens, un rôle dans la croissance des épidémies de diabète de type 2, de cancers et d’autres maladies. Les coûts, les mécanismes et la prévention. Pr. Philippe BOUCHARD - Membre de l’Académie nationale de médecine, Département d’Endocrinologie et de la Médecine de la Reproduction 2 - Massive Open Online Courses (MOOCs) Pr. Albert-Claude BENHAMOU - Conseiller à l’Agence Universitaire Francophone 3 - L’enseignement de la médecine de la médecine en Russie : nouvelles méthodes de l’enseignement à distance Pr. P.V. GLYBOTCHKO - Membre de l’Académie des Sciences de Russie 4 - Stratégie de vaccination – Les conséquences de santé publique Pr. François BRICAIRE -Chef du service des maladies infectieuses et tropicales Hôpital de La Pitié - Salpêtrière, Paris, Membre de l’Académie nationale de médecine 5 - Le programme d’immunisation national dans le cadre du concept moderne de la médecine préventive PR. N. I. BRIKO - Membre de l’Académie des Sciences de Russie, Chef de l’institut de l’épidémiologie du Ministère de la santé en Russie 6 - Les infections en pédiatrie : l’enjeu et les solutions possibles Pr. YU. V. LOBZIN - Membre de l’Académie des Sciences de Russie, Chef de l’Institut du Ministère de la santé de la Fédération de Russie 7 - Le système de santé russe dans l’environnement moderne : possibilités de stabilisation et de développement Pr. V.I. STARODOUBOV - Vice-Président de l’Académie des Sciences de Russie Conclusion du 1er Forum Franco-russe de Santé Publique et d’Innovation Médicale Pr. Ivan DEDOV - Vice-Président de l’Académie des Sciences de Russie Pr. Bernard CHARPENTIER - Vice -Président de la Fondation de l’Académie de Médecine, Président de la Fédération Européenne des Académies de Médecine 16H00 - FIN DU FORUM 13 Sponsored Symposium IV ACCESS IN NEONATOLOGY LOCAL EXPERIENCE 29th JUNE 2016 - 12:00 - 13:30 Meeting Room n°1 - Endocrinology Center 12:00 : Conference: Prof Alexander PUGACHOV Dr Ziad ASSAF - Service Néonatalogie Réanimation à l’hôpital Necker (Paris) Sponsored Symposium MEDICAL EMERGENCY & DISASTER 1st JULY 2016 - 12:00 - 13:30 Meeting Room n°1 - Endocrinology Center 12:00 : Conference: 1er Forum franco-russe de santé publique et d’innovation médicale 1-й Российско - Французский Форум «Общественное здоровье и инновации в здравоохранении» SPEAKERS 16 THURSDAY 30 JUNE 2016 TH JEAN-MARIE DRU President of FAM – The French Academy of Medicine Foundation Chairman of TBWA\Worldwide Born in 1947, Jean-Marie Dru, a graduate of HEC Business School, began his career in advertising in 1971. He is currently chairman of TBWA, a wolrdwide marketing and advertising network that operates in 140 countries with a staff of 1200 people. Jean-Marie Dru is the President of the French Academy of Medicine Foundation since 2013. He is also a professor at the Paris Institute of Political Sciences. Jean-Marie Dru has published several books on marketing and advertising issues, both in America and France. In 2008, Jean-Marie Dru was awarded the French Légion d’Honneur for his long-lasting contribution to the advertising industry and to the business world. Jean-Marie Dru was officially inducted into the Advertising Hall of Fame in New York on 11 April 2016. Prof. CLAUDE JAFFIOL Born, July- 10- 1933 ; Married ; 2 children Vice President of the Académie nationale de medicine - Honorary professor, University of Montpellier - Ex director of the department of endocrine and metabolic diseases Main fields of research: diabetes, nutrition, endocrinology 17 Prof. ANDRE-LAURENT PARODI He was graduated Doctor in Veterinary Medicine (DVM) in the Veterinary School of Alfort (University of Paris) and in Bacteriology and Immunology in Pasteur Institute in Paris. Professor of Veterinary Pathology he was Head of the Department of Veterinary Pathology in the Veterinary School of Alfort and then Director of this School. He has been a member of various French (Ministeries of High Education and of Investigation, President of the Commission for Veterinary Products registration, President of the Committee for Ethics in Animal Experimentation) and international (including WHO and European Commission) working groups and scientific Committees. He is past-President of the World and of the European Societies of Veterinary Pathologists and of the European College. His scientific investigation activities were developed in the field of Lymphoïd tissue pathology in animals with a particular interest in Retroviruses associated Malignant Lymphomas, as animal models for human medicine. He is a member and honorary President of the French VeterinaryAcademy and of the National (French) Academy of Medicine. He is Doctor Honoris Causa of the Universities of Cordoba (Spain), Bucarest (Romania), and Liège (Belgium). He is Officier dans l’Ordre national de la Légion d’Honneur, Commandeur dans l’Ordre national des Palmes Académiques, Prof. YEGOR VASSETZKY, born in 1961, graduated from the Moscow State University in 1984. After a PhD thesis in 1989, he worked as a postdoctoral fellow in Paris, Lausanne and Montpellier. Since 2002 he heads the Nuclear Organization and Pathologies laboratory at the Gustave Roussy Institute (Villejuif, France). His main research interests concern epigenetic regulation and nuclear organization in lymphomas. Yegor Vassetzky is also a head of the joint French-Russian Oncology Research Laboratory (LFR2O CNRS). FRENCH RUSSIAN COLLABORATION IN BIOMEDICINE RESEARCH Viruses and nuclear organization in lymphoid cells: implications for chromosomal translocations and gene regulation in Burkitt’s lymphoma Environmental factors play an important role in most human cancer. Burkitt’s lymphoma (BL), a rare B-cell lymphoma caused by specific chromosomal translocations resulting in the juxtaposition of the CMYC oncogene with an immunoglobulin gene locus, is a typical example of cancer strongly affected by environmental factors. Translocations that lead to exchanges of chromosome arms may disrupt this cellular order and lead to relocalization of genes within the nucleus. We have shown that c-myc gene was relocalized form the chromosomal periphery into the central perinucleolar region following translocation where it was upregulated by nucleolin. We propose a novel mechanism of carcinogenesis brought about by chromosomal translocations where the relocalization of chromosomal territories within the nuclear space leads to misregulation of translocated genes. BL is also associated with the human immunodeficiency virus (HIV-1). The molecular mechanisms of this association remain largely unknown. One of the major enigmas to solve is why HIV-1 specifically induces Burkitt’s lymphoma, and no other malignancies? Our data indicate that HIV and its protein Tat perturb the nuclear organization of B-cells inducing the prolonged colocalization of potential translocation partners, the IGH and CMYC loci. These results have important implications for early diagnostics, prevention and treatment of Burkitt’s lymphoma in AIDS patients. 18 Prof. BERNARD BAUDUCEAU DOB: September 3, 1948 Qualifications - Doctor of Medicine (thesis presented at Bordeaux on October 1, 1973) - Diploma in Tropical Medicine (December 1972) - Certificate of Higher Studies (CES) in Rheumatology and Endocrinology Hospital Qualification - Intern, Bordeaux Hospitals (competitive examination, 1972) - Physician, Armed Forces Hospitals (July 1, 1982) - Associate Professor (Professeur Agrégé), Val-de-Grâce Hospital, Paris (December 1, 1992) Professional Experience - October 1, 1977, to September 30, 1980 : Deputy Physician at Taravao Hospital (Tahiti) - October 1, 1980, to July 31, 1982 Resident, the Armed Forces Hospitals at Robert Picqué, Armed Forces Hospital (Bordeaux), Medicine Department - August 1, 1982, to August 12, 1984 Hospital Physician in the Medicine Department of Bouaké Regional Hospital (Ivory Coast) - August 13, 1984, to August 31, 1987: Deputy Physician in the Cardiovascular Disease Department, Bégin Armed Forces Hospital - September 1, 1987, to January 31, 1993 : Deputy Head of the Endocrinology Department, Bégin Armed Forces Hospital - February 1 1993 to November 2010 Head of the Endocrinology Department, Bégin Armed Forces Hospital Membership Of Learned Societies - Société de Médecine des Armées - Société Française d’Hypertension Artérielle/French Hypertension Society - Société Française d’Endocrinologie - Société Francophone du Diabète : Secretary General from 1999 to 2003 then Treasurer from 2007 to 2015 WHY THIS DIABETES EPIDEMIC: A WORLDWIDE PANDEMIC Diabetes is one of the largest global health emergencies of the 21st century. The 7th edition of the International Diabetes Federation reports that an increasingly greater number of people live with this condition each year. The global prevalence of type 2 diabetes in 2015 was 8.8% in adults, and by 2040 it will be 10.4%, i.e. an increase in the number of people with diabetes from 415 to 642 million. This epidemic is the consequence of dietary changes, reduced physical activity and genetic predisposition. Type 2 diabetes is directly linked to obesity, especially android obesity, which reflects insulin resistance. Type 2 diabetes is often associated with risk factors and can go unnoticed and undiagnosed for years. Severe complications can occur with diabetes, and it is therefore necessary to treat this disease with dietary changes and physical activity, although medication may be required in some cases. Ensuring the health of future generations is key to sustainable development. Policies that limit the intake of sugar, fat and salt are indispensable in the fight against rising rates of type 2 diabetes, and a collective approach involving civil society is essential for change. 19 Prof. JEAN-FRANCOIS GAUTIER Department of Diabetes and Endocrinology Lariboisière Hospital, Paris, France Jean-François Gautier is Professor of Medicine and Head of theDepartment of Endocrinology and Diabetes at Lariboisière Hospital, University Paris 7, Paris, France. He is also a clinical researcher in the cellular and clinical pathogenesis of diabetes at the French National Institute of Health and Medical Research (Institut national de la santé et de la recherche médicale, INSERM), Cordelier Research Centre, Paris, where he is investigating the effect of the intrauterine environment on predisposition to type 2 diabetes. Professor Gautier’s principal research interests are the pathophysiology of obesity and type 2 diabetes, and the mechanisms involved in the development of ketosis-prone type 2 diabetes, a subtype of diabetes frequently observed in Sub-Saharan Africa. He also worked on the effect of physical exercise on glucose metabolism and body fat distribution, and as a treatment of type 2 diabetes. Professor Gautier received his MD degree from Cochin-Port Royal Medical School, René Descartes University, Paris, and qualified as a specialist in endocrinology and metabolism in 1990. He obtained his PhD in Human Nutrition, Physiology and Pathophysiology from the University of Paris in 1996. Professor Gautier has published over 90 original papers and contributed to 14 handbooks. He is a member of the American Diabetes Association, the European Association for the Study of Diabetes, and the French Diabetes Society (Société Francophone du Diabète). CAN DIABETES BE PREVENTED Type 2 diabetes is an inherited disease. Indeed the risk to develop diabetes in offspring of type 2 diabetic patients is around 40%. However, taken together, genetic variants explain less than 10% of inheritance and the important role of environmental factors such as high fat diet, sedentarity and adverse foetal exposure are well recognized. Very high risk subjects are those who display glucose intolerance and women who have a history of gestational diabetes. Other risk factors have also been associated with further development of type 2 diabetes in longitudinal studies: aging, obesity, waist circumferences, ethnicity, lipid profile, blood pressure, inflammatory markers, fasting blood glucose.... Many authors had developed risk prediction models for type 2 diabetes based on simple criteria. Five lifestyle intervention programmes have been published so far (North America, Finland, China, Japan, Indian) and have shown a 50% risk reduction compared to control subjects with prediabetes. These programmes based on regular physical exercise and well balance diet, were very well structured with individual coaching so that many subjects loosed weight. While the protective effect was still observed long term after the intervention, most individuals regain weight. Metformine, Glitazones, Ascarbose, and Orlistat have been also evaluated to prevent diabetes with the highest level of efficacy for glitazones (around 70% risk reduction). In the Swedish Obesity Surgery study, bariatric surgery reduced diabetes risk by 70% in morbid obese patients. Thus, the prevention/delay of type 2 diabetes by lifestyle or drug interventions is efficient in the context of controlled trials. The question now is how to implement lifestyle risk reduction programmes in real-world setting. Prof. ANNE VANBERGUE is professor of Endocrinology and Diabetology in the Faculty of Medicine at the University of Lille 2, Lille, France. In the department of Diabetology at Lille University Hospital, she also leads a young research group at the University of Lille 2, EA 4489 “Perinatal environment and fetal growth”, devoted to the team diabetes and pregnancy. She has obtained 5 research grants from national institutions (PHRC, SFD). She has recently integrated the Philippe Froguel’s unit (CNRS UMR 8199 Genomic and Metabolic Diseases Lille). She is author or co-author of more than 57 publications in peer reviewed journals and more than 70 communications in national or international congress. Regularly invited to give lectures on Diabetes and Pregnancy, she is also the principal investigator of several ongoing clinical trials on diabetes and pregnancy. Anne Vambergue is President of the French “Diabetes and Pregnancy group” of the French Society of Diabetes. Anne Vambergue has recently been accepted as member of the European Diabetic Pregnancy Study Group. 20 DIABETES AND PREGNANCY : NEW PERSPECTIVE Diabetes in pregnancy is still considered a high-risk condition for both mother and baby. Although significant progress has been made, women with pregestational diabetes and their offspring remain to have a significantly elevated risk of multiple adverse complications. Increasing global rates of type 2 diabetes are now extending into pregnancy, with similarly poor outcomes to type 1 diabetes. Glycemic control is the most important risk factor for congenital anomaly in women with type 1 and type 2, whereas maternal obesity and social disadvantage are associated with large for gestational age neonates, especially in women with type 2. Both the preconceptional counseling and glycemic profile optimization represent a fundamental step to improve pregnancy outcomes in women with preexisting diabetes. Over the last 5-10 years, several randomized trials have offered new insight into the role of oral hypoglycaemic drugs and insulin analogues in pregnancy, while subcutaneous insulin infusion pumps and continuous glucose monitors are under scrutiny. Structured programmes using information technology and enabling access to novel technologies may facilitate our global ensuring an outcome closer to that of a pregnancy unaffected by diabetes. The relevance of minor degrees of hyperglycaemia to adverse pregnancy outcome was clearly demonstrated but translation of these data into clinical practice has proved challenging because of the continuum of risk. Long term metabolic and cardiovascular implications of hyperglycaemia during pregnancy for mother and child are now generally recognized with major implications for public health. Prof LYSE BORDIER Hôpital Bégin (Army hospital) Endocrinology Department, Saint-Mandé, France) Obtained Medical Doctorate in Lyon, 02/11/1997. Diploma of Specialised Studies (DES) in Endocrinology-Metabolism, Paris, 2004 Physician, Armed Forces Hospitals 2006 Associate Professor (Professeur Agrégé), Val de Grâce Hospital, Paris 2012 Head of the departement of endocrinology, Begin military hospital 2015 GCP Training 2015 Member of French diabetes Society 2000, French Endocrinology Society, 2000, French Army Medicine Society, 2002 180 publications as of 2016. THE HEALTH PATH OF THE DIABETIC PATIENT Diabetes due to its increasing frequency and severity of its complications is an important cause of morbidity and mortality in France. Its prevention and management represent a major public health issue. This is why the High Authority of Health published in 2014 a guide to the care pathway for type 2 diabetic This approach aims to promote a multidisciplinary care, coordinated, efficient and personalized to the patient meet its prevention and care needs. The general practitioner is at the heart of this course and therapeutic education, allowing the patient to be autonomous in its treatment plays a vital role. Several studies have evaluated the actual practices and highlight the differences with the recommendations. Several factors may explain these differences include lack of information, training or time. An awareness of the components must enable to implement corrective actions. The emergence of new digital tools such as telemedicine should also facilitate adherence to treatment course for all patients and thus improve the quality of care. 21 FRIDAY 1 JULY 2016 ST Prof BERNARD LAUNOIS 1972-199 Professor of Surgery, Head of department of Digestive surgery and transplantation to Faculty of Medicine of RENNES 2001 Full Professor of surgery University of ADELAIDE South Australia Consultant Surgeon The Queen Elizabeth Hospital, Royal Adelaide Hospital, Flinders Medical Center French Institutions President, International Committee of Academie Nationale de Médecine (2001) Past Président, French Academy of Surgery(2007) Past Président, French Society of Transplantation (1981-1984) Président, 100th French Congress of Surgery(1998) Organizer of the 1st, 2d, 3rd, 4th Seminar of Surgical Oncology Palais des Congres Porte Maillot Paris (2007, 2008, 2009, 2010) Foreign Institutions : Roll of Honor de l ’Union International contre le Cancer (UICC) Honorary Member of American Surgical Association (2009) Honorary fellow of American College of Surgeon s(2010) Honorary Professor of Department of Surgery of’ University of Hong Kong (1989) Profesorr’Ad Honorem’ of Faculté de Médicine de Montevideo(Uruguay)(2011) Member of the Court of Examiners of Royal College of Surgeons of England (1993) 22 Prof JEAN-PIERRE ARMAND He focuses his cancer research in the field of new mechanism of oncogenes’ and early drug development. Jean-Pierre Armand MD, MSc, is certified in Medical Oncology (University of Toulouse III and Paris XI)v He was recently General Director of the Institut Claudius Regaud in Toulouse . Over the last five years he has been in charge of the construction of a new cancer center, in a European research hub created in the Toulouse cancer campus (Institut Universitaire du Cancer)and opened in 2014. After a position as research fellow in Columbia University New York, Dr Armand has joined Institut Claudius Regaud in Toulouse, he was head of Medical oncology until 1984. In the next 23 years, at Institut Gustave Roussy (IGR) in Paris, he was successively CEO of the Hospital IGR3, head of the Department of Medical oncology at IGR2 and finally CMO of IGR&D, Dept of Innovation and Development at IGR. Although expert in breast, headneck, and neuro-oncology, the first field of Dr Armand was very early drug development in phase 1 and 2 of new anticancer agents . He is the founder of the IGR Phase I Unit (Ditep) in the early 80s. He did the first in human phase I in the world at IGR of numerous drugs. At present ,he and his colleagues are concentrating in Gustave Roussy DITEP on new therapies for orphan treatment cancer diseases, with a special personal investment in cancer biotechs . Dr Armand is active in the International Cancer community. He served as : • President of the European Society for Medical Oncology (ESMO), • President of the French Cancer Society (SFC) Medical Director of the Federation of European Cancer Societies (FECS/ECCO) • Chairman of the Protocol Review Committee of European Organization of Research and Treatment of Cancer (EORTC) • Chairman of Oncology at French EMA (AFSSAPS) • Member of International Boards of the American Association for Cancer Research (AACR) • Member of scientific committee of the American Society of Clinical Oncology (ASCO) and AACR • Member of the board of clinical trials at Institut National du Cancer (INCa) • chairman of the president nominating committee of ESMO He is member of the Chinese Society of Medical Oncology(CSCO) DR Jean-Pierre ARMAND is also proud to have been a mentor and teacher of multiple students, medical oncology fellows from all over the cancer world. He has (co)authored over 300 medical and scientific peer-reviewed articles and he is/was member of the Editorial Boards of Annals of Oncology, the European Journal of Cancer, Journal of Clinical Oncology, Investigational New Drugs, Anticancer Research, Clinical Cancer Research.,CISCO journal DR Armand he received - In 2008 (Stockholm) the ESMO Award as “the European oncologist of the year” - In 2013 the Targeted Anticancer Therapy (TAT) honorary award in recognition of his contribution to new drug discovery in cancer - In 2014 the European Lung cancer award in Athens he is Chevalier of French Legion d Honneur After a 5 years as CEO of Institute Claudius Regaud in Toulouse, he is now (2015) back in Paris as senior consultant in the drug development department (DITEP) in charge in biotechs at Institute GUSTAVE ROUSSY and Chief Medical Strategy Officer at Cancer campus Grand Paris. 23 AN INTEGRATED APPROACH TO TACKLING CANCER Prompted by President Jacques Chirac, the first national mobilisation plan against cancer was launched on the 24 March 2003 and proposed 70 measures structured around six operational chapters: prevention, screening, care, social support, staff training, and research.A direct result of this first Cancer Plan was the creation of the INCa, the French National Cancer Institute, which has grouped all cancer prevention stakeholders in France since 2005. In particular, its mission of coordinating cancer prevention actions includes: • Observing and assessing the cancer prevention system • Defining best practices in cancer research • Providing information to professionals and the public • Implementing medical and paramedical training actions • Funding and implementing research and development projects • Developing and monitoring joint actions between public and private bodies • Contributing to the development of European and International actions In 2003, the Cancer Plan 1 identified 7 regional Cancéropôles across the country, including the Cancéropôle Île-deFrance. In 2007, this support was renewed and accompanied by other funding amounting to nearly 10.5 million Euros for Cancéropôle Île-de-France, for the 2007-2010 period.The second 2009-2013 Cancer Plan is based on the report that Professor Jean-Pierre Grünfeld submitted to the President of the Republic, Nicolas Sarkozy, in February 2009. It follows on from the Cancer Plan 1 and is based on 30 measures divided into 118 concrete actions organised into 5 areas: • Research and innovation • Observation • Prevention and screening • Care Life during and after cancer Three major transversal themes structure and characterize the plan strategy, representing the new challenges which cancer prevention must face: • Consider health inequalities in cancer • Boost the analysis and consideration of individual and environmental factors • Strengthen the General practitioner Evaluation of the 3 rd plan which will be reconducted by the next president tell us the success and the limitation of this investment, particularly in the field of innovation and its access to patients . Prof. AXEL LE CESNE Gustave Roussy, Villejuif, Paris, France Axel Le Cesne is currently Head of the Bone/Soft Tissue Sarcoma Unit in the Department of Medical Oncology, Gustave Roussy, Villejuif, Paris, France, a post he has held since 1996. He has served at Gustave Roussy since 1989 as an intern, through a fellowship and then as a full member of the institution. Dr Le Cesne studied medicine at Cochin-Port Royal in Paris, qualifying in 1986. He obtained his Board Certification in Medical Oncology in 1991. Dr Le Cesne is the author of more than 250 research articles in the field of sarcoma, lung and breast cancer, immunotherapy and gene therapy. He is a member of several societies, including the American Society of Clinical Oncology and the European Society for Medical Oncology. He has been an active member of the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (STBSG) since 1993, chaiman of the systemic subcomitte of STBSG since 2013. He is also secretary of the French Sarcoma Group since 2001 and Co-Chairman since 2005, and a member of the Board of Directors of the Connective Tissue Oncology Society since 2010. In addition, it became a member of the Academy of Medicine of France in 2014. 24 IMPACT AND CONSEQUENCES OF THERAPEUTIC PROGRESS ON PATIENT HANDLING IN FREQUENT (LUNG CANCER) AND RARE (SARCOMAS) CANCERS Lung cancer remains by far the single most common cause of cancer-related mortality with nearly 1.6 million deaths worldwide in 2012 or nearly 20% of cancer mortality as a whole. Sequencing of the human genome has permitted more efficient identification of epigenetic mutations, tumour-suppressor-gene inactivation as well as oncogene driver mutations that are potential targets for therapy. In recent years, molecular translational research advances have heralded major breakthroughs in the understanding, diagnosis and management of lung cancer, particularly for the more common (~80%) non-small cell lung cancer (NSCLC) and there has been a major paradigm shift in the management of NSCLC. NSCLC should now be further sub-classified by histology and driver mutation if one is known or present. Whilst empirical chemotherapy with a platinum-doublet remains the gold standard for advanced NSCLC without a known driver mutation, targeted therapy is pushing the boundary to significantly improve patient outcomes and quality of life. It is now accepted that NSCLC is not a singular entity but is in fact multiple pathologies with unique molecular signatures that we are only beginning to unravel and understand. Optimal management of NSCLC now requires that tumours be screened for a range of predictive and prognostic biomarkers that help to predict sensitivity to targeted therapy and estimate prognosis respectively. The key to the future success of truly personalized oncological management will be to ensure appropriate patient selection using predictive biomarkers to optimize limited resources and minimize harm. Addressing resistance, utilizing the correct inhibitor, or combination of inhibitors, whilst minimizing adverse effects will hopefully lead to the realization of ongoing improvements in survival for patients in the future. Further to this, the real challenge will be bringing these agents into the management of patients with earlier stage disease with the hope of truly improving rates of cure for the devastating illness that is lung cancer. Same remarks and results have been observed in rare cancers such as soft tissue sarcomas representing 2% of adult cancers, with an incidence of 5.9/100000/year in EU, as established by an exhaustive epidemiological study performed in a Network of excellence in 2012. With 507 millions inhabitants in the EU, 30000 incidence cases of sarcomas are therefore expected. These tumours affect age groups from paediatric patients, to young adults up to elderly patients. For several tumours, cellular origin is unknown. Molecular analysis, combining phenotype and genomics, allows for a better classification of sarcomas, individualizing new entities and grouping some tumours. The identification of genetic alterations is often useful and sometimes mandatory, leading to a heavy and multidisciplinary multi-step treatment. Moreover, sarcomas are rare cancers but because of their association with characteristic chromosomal translocations and activating mutations they may be particularly susceptible to molecularly targeted therapies. Gastrointestinal stromal tumour (GIST) became the paradigm for targeted therapy in solid tumours owing to the success of imatinib, which has transformed the prognosis in this disease. 25 Prof. JEAN-YVES BLAY is the Director of the Centre Léon Bérard, the comprehensive cancer center of Lyon and the Rhône-Alpes region, since December 2014. He is also an oncologist, a researcher and a medical oncologist professor at the University Claude Bernard Lyon1, and a corresponding member of the French Academy of Medicine Currently President of the French Sarcoma Group / GETO, he is the network leader of the NETSARC network of reference centers for sarcoma treatment certified by the Rench National Cancer Instritue, the former PI of Conticanet ( a FP6 network of excellence), and the current PI of the FP7 project EuroSARC). He is the director of the Integrated Centre for innovation on Cancer Research of Lyon ( LYRIC). Pr. Blay has published over 500 peer-reviewed articles, including 150 in last author. He has been President of the European Organization for Research and Treatment of Cancer (EORTC) from 2009 to 2012. He has also received numerous awards such as the Hamilton Fairley Award in 2012 from the ESMO and the Henry and Mary-Jane Mitjavile prize in 2013 from the National Academy of Medicine. Pr. Blay is an active member of the European Society of Medical Oncology, the American Society of Clinical Oncology, the American Association of Cancer Research and has served as member of Scientific Committees for the ESMO and AACR meetings. He has been a reviewer for the Journal of Clinical Oncology, Blood, Cancer, Annals of Oncology, European Journal of Cancer, among others. His research interests focus on clinical and basic research in sarcomas, targeted treatment of cancer, the biology of breast carcinoma and relation between tumor immunologic microenvironment and malignant cells with the goal of clinical applications in the fields of diagnosis, prognosis and treatment. PERSONALIZED MEDICINE IN CANCER TREATMENTS : PROGRESS AND LIMITS In the last 15 years, the successes of the development of targeted agents in cancer were based on a two step strategy : 1) the identification of a key driver molecular alteration in a molecular subset of a malignancy ( eg HER2 amplification in breast adenocarcinomas) , and 2) the development of a targeted agent able to actively block the activated oncogenes. Antitumor activity of these novel agents was rapidely identified in late stages of advanced phase, in first line setting, then in the adjuvant setting occasionally. Trastuzumab, pertuzumab, imatinib, erlotinib , gefintinib, crizotinib, vemurafenib, vismodegib were identified with this two-step strategy, at a rapidly growing speed in the recent years, and are now available for the treatment of a growing number of patients. While this paradigm has probably not been exhausted, limitations are now identified in this overall strategy: 1) These driver alterations are occasionally present of other tumor types , and the application of the same treatment has not been consistently providing the same magnitude of results as in the primary tumor types where these agents were identified. This has been observed for instance in KIT mutated melanoma or thymoma, BRAF mutated colorectal cancers, etc… 2) Resistance to these kinase inhibitors emerge almost consistently, most often through the reactivation of parallel pathways, or through the emergence of resistant clones equipped with resistance mutations and selected by the treatment in a Darwinian manner. 3) Heterogeneity within the primary tumor, across metastatic sites and acquired during therapeutic pressure is one of the key driver of the emergence of resistance. 4) Unexpected primary resistance to inhibitors of suspected driver oncogenes was observed in several clinical trials with novel classes of agents (eg MDM2 inhibitors in MDM2 amplified cancers). 5) A large number of targeted oncogene treatments are multikinase inhibitors directed against kinases involved in the process of neoangiogenesis. Their activity is limited to some patients in most tumor types and biomarkers are lacking to identify responders and resistant patients. 6) Oncogenesis in the majority of human cancers result from the combination of multiple genetic and epigenetic events suggesting that the paradigm of a single strong driver may be reserved for a small proportion of cancers. 7) Immunotherapy represents another strategy , directed against neoantigens expressed in the tumor, which may allow to overcome the emergence of clonal resistance emergeing as a consequence of heterogeneity. In the presentation, we will discuss the strategies which could be developed to address these key questions for the development of targeted agents in oncology. 26 Prof. JACQUES ROUËSSÉ Born in 1940 Interne des Hôpitaux de Paris 1965-1969 MD (1969) Chef de clinique à la Faculté, Assistant des Hôpitaux 1969-1981 Medical oncologist at Institut Gustave-Rousys, Villejuif 1969-1986 Chief of one of medical oncologist departments of Institut Gustave Roussy de Villejuif – 1977-1986 Médical Director of the comprehensive cancer center of Saint-Cloud, (district of Paris) Centre René-Huguenin – 1986-2005 Associated Professor Associé de Cancérologie – Faculté de Médecine Paris-Ouest (1988) Member of the European Organisation of Research on Treatment Cancer (EORTC) Vice-Chairman, 1994-1997. Chairman of Soft tissue and bone sarcomas group 1986-1989 Membre correspondant de l’Académie nationale de médecine 2001 Membre de l’Académie nationale de médecine 2011 Chairman of the cancer committee of the French medical academy Chairman of the ’Association for cancers screening in Département des Hauts de Seine (ADK 92) (2002-) Author of more than 250 articles in international or french medical publications. TARGETED TREATMENTS, NEW PROGRESS FROM COMPLIANCE TO THERAPEUTIC EDUCATION. Breast Cancer : an example Breast Cancer is the first cancer to be treated by targeted therapy. Breast cancer is known as a cancer sensible to hormonal treatment. A the end of the sixties the discovery of hormonal receptors on the tumoral tissue allowed to distinghish tumors which will be sensitive or not to hormonal treatment .And the end of the nineties the selection of tumors with high level of HER-2 expression indicates those which be sensitive to specific immunotherapy by tastuzumab. These distinctions are available in case of decision of adjuvant treatment after the local treatment of a primary lesion or in case of metastatic situation. Prof. YVES JUILLET Yves JUILLET is the Secretary General of the Academy of Medicine Foundation. Doctor of Medicine (on 1975, Faculty of Medicine of Paris), he is a specialist of cardiology, internal medicine, medical reanimation and pharmacology. He was at the department head at Broussais hospital in Paris. During his career, he particularly dedicated himself to the harmonisation of medicine regulations between the various continents. He was the chair of different regulatory committees at European and International level. He is the past President of the drug information association and of the global corporation group on the International Conference of Harmonisation. He is a member of the National Medicine Academy. He is the honorary President of the National Pharmacy Academy ( 2013). 27 Prof. PHILIPPE BOUCHARD Philippe Bouchard earned his medical degree from the Université Pierre et Marie Curie in Paris in 1978. His medical career began in Burkina Faso where he worked as a doctor from 1972 to 1974. From 1978 to 1980, he was a research fellow at the Population Council’s Center for Biomedical Research at the Rockefeller University (New York, NY USA). Professor of Medicine since 1984, he is the former Chair of The Department of Endocrinology, and Ob Gyn (Pole GEO), at Hospital Saint Antoine, University Paris 6 (UPMC), and Director of EA 1533 “Genetics of Human Reproduction”. Philippe Bouchard is presently Professor Emeritus of Medicine, at the Pierre et Marie Curie University in Paris (Paris 6), and and is a consultant in Endocrinology, in the Department of Ob Gyn, at Hopital Foch in Suresnes. He is the past President of the Board of Endocrinology at the French Ministry of Education (CNU). Since 1989 he has been a Senior Consultant of The Population Council, in New York, and a member of the International Committee for Contraception Research (ICCR); a network of scientists and clinical investigators who conduct clinical trials to test the safety, efficacy, and acceptability of The Population Council-developed reproductive health products. Author of more than 400 publications, Philippe Bouchard is former President of the French Endocrine Society, the European Society of Gynaecology, and the French Society for Reproductive Medicine. He is the immediate past President of the European Society of Endocrinology (2011-2015). His research is related to Reproductive Endocrinology and Genetics. Among several distinctions, he is Doctor honoris causa of the University of Liege since 2002. He was awarded the Legion d’honneur in 2001. He has been elected as a permanent member of the National Academy of Medicine in 2014. ENDOCRINE DISRUPTION, A GLOBAL RISK WITH EXTREME CONSEQUENCES: A PLEA FOR UNIVERSAL RESEARCH Although, by nature, different from the classical hormones, an endocrine-disrupting chemical (EDC) is a chemical or mixture of chemicals in the environment that can interfere with any aspect of hormone action (androgens, estrogens, thyroid hormones, retinol, Aryl Hydrocarbone, PPAR…). WHO defined an EDC as “...an exogenous substance or mixture that alters the function(s) of the endocrine system and consequently causes adverse effects in an intact organism, or its progeny, or (sub)populations” (WHO/IPCS 2002). The list of potential EDCs is huge: including polychlorinated biphenyls, dioxin, Perfluoroalkyls, solvents, Phtalates, BPA, DDE, pesticides, Polybrominated diphenyl esters… These chemicals can act through pathways involving classical nuclear or membrane hormone receptors, but can also interfere with neuroendocrine regulation, and impact on growth factor signaling, and/or through epigenetic mechanisms. The field, and its extraordinary impact, was revealed with the use of pesticides, in the 60s, mostly DDT and derivatives, but also in the medical field with the consequences of the treatment with DES in pregnant women. The transgenerational potential of the EDC treatment was thus demonstrated. One of the difficulties in studying the toxicity of EDCs is that their toxicity can be observed following exposure to the chemical(s) at low levels. Also several EDC can combine their toxicity in a “cocktail” mechanism, finally, they can exert their deleterious effects in a non linear manner. Most importantly, their toxicity can be delayed particularly when administered in pregnant women or in children (The Dohad mechanism: Developmental Origins of Health and Diseases as postulated by DJBarker et al.) . Linking specific endocrine- disrupting chemicals to childhood illnesses is extremely challenging and may not be possible. Individual susceptibility is also a component of the potential consequences to EDC exposure. Finally, multiple routes of administration are possible: Oral, inhalation, dermal absorption, IV… These mechanisms of action create huge difficulties to recognize the toxic products, since the side effects may not be observed by the classical toxicologic studies. Recent analysis, using mathematical simulations of the putative cost of the consequences of EDC exposure, suggest a cost of 200 bn € every year in EU! This include potential consequences in several medical fields: Infertility, Male and Female Reproductive Dysfunction, prostate and breast Cancers, birth defects, Obesity, Diabetes, cardiovascular diseases, immune regulation and Neurobehavoural and learning dysfunction… 28 At this stage it is crucial to organize serious epidemiologic surveys to replace the present expert opinions, and avoid the deleterious consequences of the endless discussions about potential conflicts of interest of experts and political authorities. The combination of epidemiologic but also toxicologic, and experimental analyses, will improve our knowledge on this complex and worrisome field and will impose the necessary precautions presently based on not always founded assumptions based on chemicals that are not EDCs. Prof. ALBERT-CLAUDE BENHAMOU Paris, France - Professor of Vascular Surgery, Pierre et Marie Curie University, Paris. - Member of the National Academy of Surgery - Director of the « Francophone Digital University of Health & Sports Sciences » (« Université Numérique Francophone des Sciences de la Santé et du Sport » www.unf3s.org) - Project Manager for the Office of the Secretary of State for Higher Education and Research, France - Project manager for the Agency of french speaking universities (AUF) HOW TO DEVELOP A RUSSIAN FRENCH DIGITAL ACADEMIC SPACE ? Our objective is the digital development of a national and international academic space, especially french and englishspeaking, as a part of the French-Russian cooperation. The french digital university offers to day via a national portal : www.sup-numerique.fr For those who want to teach or learn «online», this new portal is a one-stop shop dedicated to higher education by digital technology. 1/ the new agenda of MOOCs of the French FUN MOOC program, devoted to all the higher education disciplines : http://www.sup-numerique.gouv.fr/pid33135/moocs-calendrier-des-cours-en-ligne-ouverts-et-massifs.html It is also focused on the field of public health and medical innovation. For instance you can access to the first MOOC devoted to vaccinology produced by the Pasteur Institut: https://fun.libcast.com/resource/video-1850/flavor/video/ fun-hd.mp4 2/ http://www.sup-numerique.gouv.fr/pid33288/moteur-des-ressources-pedagogiques.html: the very powerfull specific search engine, featuring over 30,000 training ressources. This motor is opened to students, teachers, researchers, professionals and more generally to each citizen, providing free access to the digital learning resources: courses, case studies, tutorials, interactive lessons, conferences, offered as text, video, web documentaries, software or websites. The indexing motor is provided in the Open data format.These resources will be enriched over time. 3/ www.unf3s.org: is the portal of the « digital university for health and sport sciences » offers on line programmatic teaching ressources and MOOCS. 3/ We hope to develop between Russia and France of a powerfull partnership and fruitful exchanges, driving to an international web platform offering, free access to new coproductions of digital teaching resources and to digital online training programs, including with bi-lingual MOOCS, covering all subject areas and offering recognised diplomas and reputable certifications. 29 Prof. FRANÇOIS BRICAIRE Former Intern Hospitals of Paris - Former Senior registrar - Hospital doctor of Paris (PH 1983); University professor UNIVERSITY DEPARTMENT Paris VI Pierre and Marie Curie 1992. Doctor clinician specialized in Infectious and tropical Diseases - Awarded a diploma in Inner medicine. Department head of Infectious diseases at the Hospital of Pitié-Salpêtrière ( 1995-2013 ), Head of the Pole Infection-Immunité-Inflammation of the Hospital of Pitié-Salpêtrière ( 2011-2013 ). Member of the National Academy of Medicine: 4th Public Healthcare division; president of the international operations of the French Red Cross. Chevalier of the Legion of Honour; officer of the National Order of the Merit. THE VACCINAL STRATEGY IN FRANCE The vaccinal strategy in France bases on decisions taken by the Ministry of Health, helps by authorities such as the technical committee of the vaccinations. This allows every year to specify by publication of the vaccinal calendar, the novelties were considered necessary, either in supplement, or possibly set back. In a global way, the vaccinations are either compulsory, certain for all, some orientees towards targeted populations, or recommended but with 1 idea that they are made. They are among others proposed according to the ground (age, immunosuppressed, traveler). The strong antivaccinal tendency which rages in France at present, obliges a reflection, has proposals, and in the decisionmaking to fight against this grave phenomenon regarding. Prof. BERNARD CHARPENTIER received his MD and graduated in Nephrology from Paris University School of Medicine in 1975. He is full Professor in Medicine in Paris-Sud 11 University since 1983, medical Consultant and was Head of the Department of Nephrology, Dialysis and Transplantations in the University Hospital of Bicêtre (1992-2011). He was Director of several CNRSINSERM-University Paris-Sud 11 research units devoted to Immunology and Immunoregulation (CNRS UPR 277-420; INSERM U542-1014). He is (co)author of more than 400 pubmed-indexed publications on Nephrology and Transplantation. He was member of several Editorial Boards of immunology and transplantation journals and of immunology, nephrology, and transplantation societies. He acts as a consultant for several International, European and National Advisory Committees. He is member of the Ethical and Sanction Committee (CODEEM) (2011-2014) of the French Pharmaceutical Companies Union (LEEM). He was Dean of the Faculty of Medicine Paris-Sud (1998-2008), President of the French Medical Deans’ Council (2003-2008), President of the French Transplant Society (1997-2000), President of the European Society for Organ Transplantation (ESOT) (2005-2007), Co-Chairman of the XVth ESOT Congress (Paris-2009). He was elected as full member of the French Academy of Medicine (2010), Council Member of the Federation of European Academies of Medicine (FEAM-2012), FEAM Vice-President (2014) and now FEAM President (2015). He is Officier de la Légion d’Honneur, Officier de l’Ordre du Mérite, Chevalier des Palmes Académiques, Médaille d’Honneur du Service de Santé des Armées. His field of interest are mainly focused in transplantation medicine, basic immunology, immunoregulation and immunosuppressive drugs. 30 RUSSIAN TRANSLATION XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX FRENCH TRANSLATION XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Pr. Ivan DEDOV - Vice-Président de l’Académie des Sciences Russe RUSSIAN TRANSLATION XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXX L’année 2016 marque les 50 ans de la coopération franco-russe dans le domaine scientifique et technologique, au moment même où la Fondation de l’Académie de Médecine organise ce 1er Forum de santé publique et d’innovation médicale. C’est l’occasion de renforcer davantage les échanges entre nos deux pays et d’assurer la continuité de notre collaboration. Depuis des décennies, les représentants de la médecine russe et de la médecine française se rencontrent, tissent des liens de plus en plus étroits et s’enrichissent de leurs savoirs partagés. Le Forum s’inscrit dans cette tradition. Il a pour objet d’apporter aux médecins et, par conséquent, aux patients de ces deux pays le meilleur des deux médecines Jean-Marie DRU - Président de la Fondation de l’Académie de Médecine Avec la participation de: Et le soutien de :
